Interferon-α: An effective adjuvant for peptide-based cytotoxic T-cell vaccines

Kurume Medical Journal

Volumn 48, Issue 2, 2001, Pages 171-174

  Takasu, Hideo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant; CTL; Interferon ; Vaccine

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; SYNTHETIC PEPTIDE; VIRUS NUCLEOPROTEIN;

ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG FORMULATION; FEMALE; IMMUNIZATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; OSMOTIC PUMP; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION;

EID: 0034872111     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.48.171     Document Type: Article

References (12)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-1647.
2. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-352.
3. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187:277-288.
4. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H et al. Identification of gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59:4056-4063.
5. Arnon R, and Horwitz RJ. Synthetic peptides as vaccines. Curr Opin Immunol 1992; 4:449-453.
6. Claassen E, de Leeuw W, de Greeve P, Hedriksen C, and Boersma W. Freund's complete adjuvant: An effective but disagreeable formula. Res Immunol 1992; 143:478-483.
7. Edelman R. An update on adjuvants in clinical trial. AIDS Res Hum Retrovirus 1992; 8:1409-1411.
8. Disis ML, Bernhard H, Shiota FM, Hand L, Gralow JR et al. Granulocyte-macropharge colony -stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996; 88:202-210.
9. Ahlers JF, Dunlop N, Ailing DW, Nara PL, and Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. J Immunol 1997; 158:3947-3958.
10. Belardelli F, and Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996; 17:369-372.
11. Luft T, Pang KC, Thomas E, Hertzog P, Hart DNJ et al. Type I IFNs enhance the terminal differentiation of Dendritic cells. J Immunol 1998; 161:1947-1953.
12. Hiroishi K, Tuting T, and Eotze MT. IFN-α expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 2000; 164:567-572.